Wednesday, 21 Aug 2019

TNF inhibitor

Datesort descending Type Title Save
02 Nov 2017 News CALM Study: Tight Control with Anti-TNF Wins in Crohn's Disease
04 Nov 2017 Social RT @_connectedcare: I typically use this 2nd line for those not responding to TNFi in AS. What about you? #ACR17 https://t.co/taFDHiKqhx
04 Nov 2017 Social RT @psufka: @_connectedcare My approach: If primary nonresponse to TNFi -> IL-17. If secondary nonresponse to TNFi -> 2nd TNFi #ACR17
04 Nov 2017 Social RT @KDAO2011: Dr L Gensler #ACR17: tobacco use decrease efficacy of TNF inhibitors
06 Nov 2017 Social RT @japaoli19: Crib study shows no detectable levels of CZP on infants umbilical cords #ACR17 @RheumNow https://t.co/7C1ctxv76c
06 Nov 2017 Social RT @uptoTate: Anti-TNF drugs could be safe following paternal exposure in pregnancy outcomes. #ACR17 @RheumNow #1312 https://t.co/G4s9zyOhoY
07 Nov 2017 Social RT @DrPetryna: #2453 #acr17 no difference in disease activity&PRO with ADA after MTX d/c at 6mo:LDA 42%ADAvs40%ADA+MTX @RheumNow https://t.…
08 Nov 2017 Social RT @uptoTate: 84% of cardiac sarcoidosis pts refractory to immunosuppressive tx responded to TNFi. #ACR17 @RheumNow #2904 https://t.co/vTOL…
21 Nov 2017 ACR Video Dr. Rachel Tate: Sarcoidosis and TNF Inhibitors
07 Dec 2017 News Infliximab Does Not Increase Perioperative Infection
08 Dec 2017 News Why TNF Inhibitors May Work in Some Autoinflammatory Patients
12 Jan 2018 Social 188 PsA pts receive 1st TNFi, 27% D/C by 24 mos (1/3 for primary inefficacy, 22% secondary inefficacy, 43% adverse events) Predictors of failure = female or metabolic syndrome-co-morbidities (HR = 2.65). https://t.co/VRdikUSQ0f
24 Jan 2018 News PRESERVE Study: HAQ, BMI and Age Predict Responses to Combo Therapy
25 Jan 2018 News Anti-Drug Antibodies Partly Explain Secondary TNF Inhibitor Failures
25 Jan 2018 News Obesity Outweighs Psoriasis in Comorbidity Risk with Children
26 Jan 2018 Social RheumNow Wk in Review is up. Discussing MPO bronchiectasis, $$ biologics, comorbidity in myositis, secondary TNF failure & ADAbs. Listen here https://t.co/wmVyjrzOB1 Watch there https://t.co/32q2qojDZC
10 Feb 2018 Social RT @uptoTate: Likelihood of achieving remission in patients who’ve failed one TNFi. Dr. M. Genovese #RWCS @RheumNow https://t.co/kFt0InT5q5
12 Feb 2018 Social RT @uptoTate: Obesity as a predictor for poor TNFi response in IBD. Dr. U. Mahadevan #RWCS @RheumNow https://t.co/nmCljYcaqJ
20 Feb 2018 Social PANTS study:Personalized anti-TNF Therapy in Crohn Disease tests real-world eficacy, safety & immunogenicity of infliximab vs biosimilar CT- P13 vs adalimumab. Wk 54 remission rate was 40% INFX, 40% CTP13 & 34% in ADA; immunogenicity was 26%, 28%, 11% https://t.co/irhImH6ipP
20 Feb 2018 News Pediatric Use of TNF inhbitors Does Not Increase Malignancy Risk